El Dr Francesc Balaguer está desarrollando una vacuna basada en células dendríticas para la #SíndromeDeLynch. La vacuna "entrena" al sistema inmune para que detecte células mutadas incluso antes de que aparezca el tumor!  #ColorectalCancerAwarenessMonth Hospital Clínic IDIBAPS

And also next tuesday, in Digestive Disease Week, we will be presenting our work from #SECOC consortium about a possible new risk factor for #EOCRC: Telomere length. IBSAL Fight Colorectal Cancer CGA-IGC Digestive Disease Week American Gastroenterological Association (AGA) Digestive Cancers Europe European Society of Coloproctology my_UEG FightEAOCRC @AbelMartel10

See our latest work focused on identifying new risk markers for Early-Onset Colorectal Cancer #DDW2023 #EOCRC 📍Poster # Tu1127 Digestive Disease Week

There's still time to register for the Young-Onset Colorectal Cancer Virtual Patient Conference on May 20. Hear insights from our experts and connect with other young patients and survivors in a supportive community. fal.cn/3ylGT #ColorectalCancer #EndCancer

MD Anderson is again #1 in the nation for cancer care in @USNews’ “Best Hospitals” ranking: bit.ly/3Oh6k4v Thanks to all who make this possible: our faculty, employees, trainees, students, volunteers, donors, advocates, partners, patients and caregivers. #BestHospitals

▶️ Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer 📝 IJMS MDPI 👥 @AbelMartel10 JOSÉ PEREA GARCÍA Francesc Balaguer mdpi.com/1422-0067/24/4…

Coverage of out finding for spatial relationship of PD-1 and PD-L1 in dMMR metastatic CRC. Stay tuned for our validation data. newsnetwork.mayoclinic.org/discussion/may…

No se si será el mejor Servicio de Oncología, es difícil saberlo. Sí creo está formado por grandes médicos, humanos,trabajadores y comprometidos con la calidad en la atención al paciente, que es nuestro principal objetivo. Son un lujo de equipo todos y a todos ellos: gracias!

1/ Do precancers in #LynchSyndrome (LS) patients generate #neoantigens that could be targetable with #vaccines to intercept #cancer development before tumor formation? Check out our study published in Gastroenterology 🚨🤩 Eduardo Vilar Fahriye Duzagac gastrojournal.org/article/S0016-… 🧵👇

1/Excited to share our latest study showing that RNA sequestration in P-bodies sustains myeloid leukemia - now out in Nature Cell Biology! nature.com/articles/s4155…. 🧵 below:

Excited to share my first manuscript in the Bruno Di Stefano, now out in @EMBOReports! 🎉 We demonstrate how two transposable elements, MER51B and LTR5_Hs, serve as selective indicators of human pluripotency states embopress.org/doi/full/10.10…. 🧵 below:

Outstanding and insightful talk on epigenetics and its clinical applications in oncology by Manel Esteller at MD Anderson Cancer Center

Just released!!

Excited to share our #multiomics study of who was the world's #oldest living person! Our research on this record-breaking #supercentenarian suggests that, under certain conditions, #aging and #disease can become decoupled—challenging the common belief that they are inherently

Just released our latest comprehensive review on neoantigen vaccines in cancer prevention. MD Anderson Cancer Center Neoantigen Vaccines in Cancer Prevention : The Cancer Journal journals.lww.com/journalppo/abs…

Lynch Syndrome (LS) carriers have a 10-20x increased lifetime risk for developing colorectal cancer (CRC)- Chase Bowen & ASCI member Eduardo Vilar MD Anderson Cancer Center build on recent studies to show EZH2 inhibition modulates the immune landscape in a LS-CRC mouse model & provide

Just landed in Chicago for #AACR25! Ready to connect, share science, and strengthen our cancer research community MD Anderson Cancer Center!

Happy to present at #AACR25 our work on the interception of FAP-associated colorectal cancer through WNT/β-catenin pathway modulation. Proud to share our research from MD Anderson Cancer Center!

Tumor inflammation predicts better response to nivolumab alone in MSI-H CRC, while high mutational burden predicts benefit from nivolumab + ipilimumab. Our Nat Comm paper dives into CM142 and PD1 ± CTLA4 predictors with lead of Michael overman. rdcu.be/eJHmS #crcsm

Happy to attend the 3rd Annual James P. Allison Institute Scientific Symposium — a fantastic opportunity to exchange ideas in immunology and cancer research. Grateful for the insights shared by distinguished leaders in the field, including five Nobel Laureates. MD Anderson Cancer Center